• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZUO Luoyi,YANG Yong.Research progress on tumor in situ vaccines[J].Journal Of Pharmaceutical Research,2024,43(6):521-528,567[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3201times   Download 3016次 QR Code for this article
Scan with your phone!
肿瘤原位疫苗研究进展
卓烙伊,杨勇
Font:Larger+|Default|Smaller-
(中国药科大学基础医学与临床药学学院,江苏 南京 211198)
摘要:
肿瘤疫苗被认为是一种有前景的肿瘤免疫治疗方式,但肿瘤自身的高异质性和高突变率极大地限制了传统肿瘤疫苗的开发。相比传统肿瘤疫苗,肿瘤原位疫苗直接将患者的肿瘤灶自身变为“抗原工厂”,具有全身毒性低、生物利用度高、个性化程度强、时间经济成本小等多种优点,具有巨大的治疗潜力和临床转化价值。肿瘤原位疫苗通过诱导肿瘤局部发生免疫原性细胞死亡,促进肿瘤抗原及免疫激活介质的释放,启动或重启机体被沉默的“肿瘤-免疫循环”,并进一步诱导产生肿瘤特异性的免疫记忆。本文聚焦于肿瘤原位疫苗,对其抗肿瘤作用机制,具有关键临床结果的具体策略进行了详细介绍,揭示肿瘤原位疫苗的应用潜力与挑战,为肿瘤原位疫苗的设计提供理论参考。
关键词:  肿瘤  原位疫苗  免疫治疗
DOI:10.13506/j.cnki.jpr.2024.06.001
基金项目:国家自然科学基金面上项目(No.82173858)
Publication Date:June 25, 2024
Research progress on tumor in situ vaccines
ZUO Luoyi,YANG Yong
(School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China)
Abstract:
Tumor vaccine is considered to be a promising immunotherapy method for tumors, but the high heterogeneity and mutation rate of tumors themselves greatly limit the development of traditional tumor vaccines. Compared with the traditional tumor vaccine, the tumor in situ vaccine can directly transform the tumor lesion itself into an "antigen factory", which has many advantages such as low systemic toxicity, high bioavailability, strong personalized degree, low time and economic cost, and has great therapeutic potential and clinical transformation value. It can induce local immunogenic cell death in tumors, promote the release of tumor antigens and immune-activating mediators, initiate or restart the "tumor-immune cycle" that has been silenced in the body, and further induce tumor-specific immune memory. This paper focuses on tumor in situ vaccine, introduces in detail its anti-tumor mechanism and specific strategies with key clinical results, reveals the application potential and challenges of tumor in situ vaccine, and provides theoretical references for the design of tumor in situ vaccine.
Key words:  Tumor  In situ vaccine  Immunotherapy
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.